Biotechs move across borders to accelerate and create asset value. But as regulatory strategy advances in one region and execution begins in another, transition risk emerges.
Enter HiRO. Designed for this moment.
A Modern Way To Think Cross-Border Discipline.
If this perspective resonates, share a few details below to continue the conversation.
Your privacy matters. We respect your trust and take data privacy seriously. The information provided will only be used to connect you about interested services.
Cross-Border Is The Modern Move
The Tufts Center for the Study of Drug Development estimates the cost to bring a new drug to market at over $2.6 billion. As development becomes multi-region, protecting asset value during regulatory transition becomes critical.
Source: Tufts CSDD
In global development, 30–40% of clinical trials experience delays, often driven by operational and coordination challenges across regions. It’s rarely the science. It’s the regulatory-to-execution transition — where strategy advances, execution lags, and accountability fragments. Source: Deloitte
Our Approach To Closing Cross-Border Gaps
HiRO links regulatory strategy, biometrics, and multi-region execution into one continuous operating model.
Regulatory Strategy Alignment
Advancing regulatory strategy across borders with continuity into execution.
Multi-Region Data Continuity
Harmonized biometrics across regions to protect data integrity.
Seamless Transition to Trial Execution
Reducing exposure at the point where most CRO models fragment.
Asset Value Protection
Designed to preserve value during regulatory advancement and expansion.
Sponsors Moving Cross-Border
Trust The Global Team At HiRO
Here’s what sponsors say about working with HiRO – the modern global CRO.
“We are currently involved in
a fast-paced multi-center clinical trial in Australia. The HiRO team has done an excellent job at identifying clinical study sites, organizing the start of the study, and executing the study within the time frame that we wanted. They have excelled at developing productive relationships with clinical sites to keep them engaged in our study and stay on budget.
I highly recommend HiRO and their team to anyone looking at the prospect of starting a clinical trial in Australia.
Medical Technology Startup
“I have truly loved working with the HiRO team!
Your support and enthusiasm contributed to the success of our study, and I’ve shouted that message loud and clear to the folks within our company. Your CRAs come from a different CRA planet – their quality of work, commitment, responsiveness and ability to foster relationships with the investigator sites puts them a notch above any other CRA team I’ve ever had the opportunity to work with. And your fab PM – in one word, rockstar!! Thank you for listening to all my rants and raves and just driving your team to achieve results without requiring any babysitting whatsoever. It’s been a pleasure.”
Major Pharmaceutical Company (NASH Study)
“It was a pleasure to work with HiRO
as they managed all aspects of our clinical study including the regulatory submissions, monitoring, and data management. HiRO and their people formed a capable, competent, and efficient partner in this process, meeting tight deadlines and retaining high quality standards. Any queries from the investigational sites, and us, were addressed quickly and to everybody’s satisfaction. When we needed them they were there, flexible with their time and with a ‘can-do’ attitude.”
Medical Device Company
Ready To Close The Ga p?
If cross-border advancement is part of your strategy, let’s talk about how you’re managing the regulatory transition.
